# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0001213900-23-009573
**Filing Date:** 2023-2
**Character Count:** 24577
**Document Hash:** 3732081b34f0b005e2e64ac78b91bb2d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-009573.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001213900-23-009573

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**EFFECTIVENESS DATE**: 20230209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269655
- **FILM NUMBER:** 23601651

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

**As filed with the U.S. Securities and Exchange Commission on February 9, 2023.**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT**

**UNDER THE SECURITIES ACT OF 1933**

**REVELATION BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**<u>DELAWARE</u>**

(Jurisdiction of incorporation or organization)

---

| | |
|:---|:---|
| **2834** | **84-3898466** |
| (Primary Standard Industrial <br> Classification Code Number) | (I.R.S. Employer <br> Identification Number) |

---

<u>4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122</u>

(**Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)**

<u>650-800-3717</u>

(**Registrant's telephone number, including area code)**

James Rolke

Chief Executive Officer

Revelation Biosciences, Inc.

4660 La Jolla Village Drive, Suite 100

San Diego, California 92122

650-800-3717

**(Name, address and phone number of agent for service)**

Copies of Communications to:

---

| | |
|:---|:---|
| J.P. Galda, Esq. | Robert F. Charron, Esq. |
| J.P. Galda & Co. | Ellenoff Grossman & Schole LLP |
| 40 East Montgomery Avenue LTW 220 | 1345 Avenue of the Americas |
| Ardmore, Pennsylvania 19003 | New York, New York 10105 |
| (215) 815-1534 | (212) 370-1300 |

---

**Approximate date of commencement of proposed sale to the public:** As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒. 333-268576

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement shall become effective upon filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE**

This Registration Statement is being filed by Revelation Biosciences, Inc. (the "*Company*") pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of $7,730,250 in additional (i) shares of the Company's common stock, par value $0.001 per share (the "*common stock*"), (ii) pre-funded warrants to purchase shares of our common stock, (iii) warrants to purchase shares of our common stock (together with the pre-funded warrants, the "warrants") and (iv) shares of common stock issuable upon exercise of the Warrants. The contents of the Registration Statement on Form S-1 (Registration No. 333-268576), as amended, including the exhibits and powers of attorney included therein (the "*Prior Registration Statement*"), which was declared effective by the Securities and Exchange Commission on February 9, 2023, are incorporated by reference in this Registration Statement. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

The required opinion and consents are listed on the Exhibit Index attached hereto and filed herewith.

**ITEM 16. Exhibits.**

The following documents are filed as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 5.1\* | [Opinion of J.P. Galda & Co. as to the validity of the shares of Common Stock of Revelation Biosciences, Inc.](ea173059ex5-1_revelation.htm) |
| 23.1\* | [Consent of Baker Tilly US, LLP, independent registered public accounting firm of Revelation Biosciences, Inc.](ea173059ex23-1_revelation.htm) |
| 23.2\* | [Consent of J.P. Galda & Co. (included as part of the opinion filed as Exhibit 5.1 hereto and incorporated herein by reference).](ea173059ex5-1_revelation.htm) |
| 24.1<sup>(1)</sup> | [Power of Attorney (contained on signature page to the Prior Registration Statement).](http://www.sec.gov/Archives/edgar/data/1810560/000121390022067716/ea167626-s1_revelation.htm#x_001) |
| 107\* | [Registration fee table](ea173059ex-fee_revelation.htm) |

---

\* Filed Herewith

(1) Previously filed as an exhibit to Revelation Biosciences, Inc.'s
Registration Statement on Form S-1, as amended (File No. 333-268076).

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, California, on February 9, 2023.

---

| | |
|:---|:---|
| Revelation Biosciences, Inc. | Revelation Biosciences, Inc. |
| By: | *James Rolke\** |
|  | James Rolke |
|  | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this Amendment No. 1 to Registration Statement has been signed, as of February 9, 2023, by the following persons in the capacities indicated below.

---

| | |
|:---|:---|
| BY: | *James Rolke\** |
|  | Chief Executive Officer and Director |
| BY: | *George Tidmarsh\** |
|  | Chairman and Director |
| BY: | */s/ Chester S. Zygmont, III* |
|  | Chief Financial Officer and Principal Accounting Officer |
| BY: | *Jennifer Carver\** |
|  | Director |
| BY: | *Jess Roper\** |
|  | Director |
| BY: | *Curt LaBelle\** |
|  | Director |

---

---

| | | |
|:---|:---|:---|
| \* | By: | /s/ Chester S. Zygmont III, Attorney-in Fact |

---

## Exhibit 5.1

**Exhibit 5.1**

J.P. Galda & Co.

Attorneys-at-Law

40 East Montgomery Avenue, LTW 220

Ardmore, Pennsylvania 19003

Telephone: 215-815-1534

February 9, 2023

Revelation Biosciences, Inc.

4660 La Jolla Village Drive, Suite 100

San Diego, California 92122

Ladies and Gentlemen:

---

| | |
|:---|:---|
| **Re:** | **<u>Registration on Form S-1</u>** |

---

We refer to the Registration Statement on Form S-1 (Commission File No. 333-268576) filed by Revelation Biosciences, Inc., a Delaware corporation (the "Company"), with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act") (as amended, the "Registration Statement"). The Registration Statement relates to the registration under the Securities Act of: (i) up to 1,898,469 shares of common stock, par value $0.001 per share (the "Common Stock"); (ii) up to 3,796,938 warrants (the "Class C Common Stock Warrants"), to be offered and sold at a combined public offering price with the Common Stock, which is immediately exercisable for one share of Common Stock and will expire five years from the date of issuance; (iii) up to 3,796,938 shares of Common Stock issuable upon exercise of the Class C Common Stock; and (iv) to any purchaser whose purchase of Common Stock in this offering would otherwise result in any such purchaser, together with its affiliates, beneficially owning more than 4.99% (or, at the election of such purchaser, 9.99%) of the outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants (the "<u>Pre-Funded Warrants</u>") in lieu of shares of the Common Stock that would otherwise result in such purchaser's beneficial ownership exceeding 4.99% (or, at the election of such purchaser, 9.99%) of the outstanding Common Stock, at the purchase price for each Pre-Funded Warrant will equal the per share public offering price for the Common Stock in this offering less the $0.0001 per share exercise price of each such Pre-Funded Warrant, which will be exercisable upon issuance and will not expire prior to exercise. The shares of Common Stock registered in the Registration Statement, including the shares of Common Stock underlying the Class C Common Stock Warrants and the Pre-Funded Warrants, are refereed to herein as the "<u>Shares</u>."

This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

We have examined and relied upon copies of the Registration Statement, the exhibits thereto, including, the form of Class C Common Stock Warrant and the form of Pre-Funded Warrant. We have also examined and relied upon copies of the Company's certificate of incorporation, as restated and amended, in effect on the date hereof (the "<u>Certificate of Incorporation</u>"), the Company's bylaws, as amended, in effect on the date hereof (the "<u>Bylaws</u>") and the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the issuance of the Shares, the Class C Common Stock Warrants and the Pre-Funded Warrants by the Company (the "<u>Resolutions</u>"). We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.

Based on the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Shares will be validly issued, fully paid and non-assessable when (i) the Registration Statement, as finally amended, shall have been declared effective under the Securities Act; (ii) the Company's board of directors or a duly authorized committee thereof shall have duly adopted final resolutions establishing the pricing and related financial terms of the Shares; and (iii) certificates representing the Shares shall have been duly executed, countersigned and registered and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof, or, if any Shares are to be issued in uncertificated form, the Company's books shall reflect the issuance of such Shares to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Class C Common Stock Warrants will constitute valid and binding obligations of the Company when (i) the Registration Statement, as finally amended, shall have been declared effective under the Securities Act; (ii) the Company's board of directors or a duly authorized committee thereof shall have duly adopted final resolutions establishing the pricing and related financial terms of such Class C Common Stock Warrants and the issuance and sale of the shares of Common Stock issuable upon exercise of such Class C Common Stock Warrants; and (iii) instruments representing such issue of Class C Common Stock Common Warrants shall have been duly executed, countersigned and issued and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Pre-Funded Warrants will constitute valid and binding obligations of the Company when (i) the Registration Statement, as finally amended, shall have been declared effective under the Securities Act; (ii) the Company's board of directors or a duly authorized committee thereof shall have duly adopted final resolutions establishing the pricing and related financial terms of such Pre-Funded Warrants and the issuance and sale of the shares of Common Stock issuable upon exercise of such Pre-Funded Warrants; and (iii) instruments representing such issue of Pre-Funded Warrants shall have been duly executed, countersigned and issued and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof.

Our opinions are subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting creditors' rights generally and to general equitable principles (regardless of whether considered in a proceeding in equity or at law), including concepts of commercial reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief.

For purposes of this opinion letter, we have assumed that (i) at the time of the issuance, sale and delivery of any Shares, the Certificate of Incorporation, the Bylaws and the Resolutions will not have been modified or amended and will be in full force and effect, (ii) that the consideration paid for each of the Shares will not be less than the par value thereof and (iii) the Class C Common Stock Common Warrants and the Pre-Funded Warrants will each be in the form reviewed by us.

We express no opinion as to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the validity, binding effect or enforceability of any provision of the Warrants relating to choice of governing law;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the validity, binding effect or enforceability of any provision of the Warrants containing any purported waiver, release, variation, disclaimer, consent or other agreement of similar effect (all of the foregoing, collectively, a "<u>Waiver</u>") by the Company under the Warrants to the extent limited by provisions of applicable law (including judicial decisions), or to the extent that such a Waiver applies to a right, claim, duty, defense or ground for discharge otherwise existing or occurring as a matter of law (including judicial decisions), except to the extent that such a Waiver is effective under, and is not prohibited by or void or invalid under provisions of applicable law (including judicial decisions); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the validity, binding effect or enforceability of any provision of the Warrants relating to forum selection or submission to jurisdiction (including, without limitation, any waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum).

Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware (including the statutory provisions, all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the foregoing) and is based on these laws as in effect on the date hereof. We express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or other state law, rule or regulation relating to securities or to the sale or issuance thereof.

We hereby consent to the filing of this letter as an exhibit to the Registration Statement. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the United States Securities Act of 1933, as amended, or the rules and regulations of the SEC thereunder.

---

| |
|:---|
| /s/ Joseph P. Galda |
| J.P. Galda |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement (No. 333-268576) and Prospectus on Form S-1/A of Revelation Biosciences, Inc. of our report (which expresses an unqualified opinion and includes an explanatory paragraph relating to the Company's ability to continue as a going concern) dated April 15, 2022, relating to the financial statements of Revelation Biosciences Inc., as of and for the year ended December 31, 2021 appearing in this Registration Statement and Prospectus on Form S-1/A.

We also consent to the reference to our firm under the heading "Experts" in such Registration Statement and Prospectus.

/s/ Baker Tilly US, LLP

San Diego, CA

February 9, 2023

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

**FORM S-1**

(Form Type)

**Revelation Biosciences, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered and Carry Forward Securities</u>

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security <br> Type** | **Security <br> Class <br> Title** | **Fee <br> Calculation <br> or Carry <br> Forward Rule** | **Amount <br> Registered** | **Proposed <br> Maximum <br> Offering <br> Price Per <br> Unit** | **Maximum <br> Aggregate <br> Offering <br> Price<sup>(1)(2)</sup>** | **Fee <br> Rate** | **Amount of <br> Registration <br> Fee** | **Carry <br> Forward <br> Form <br> Type** | **Carry <br> Forward <br> File <br> Number** | **Carry <br> Forward <br> Initial <br> effective <br> date** | **Filing Fee <br> Previously <br> Paid In <br> Connection <br> with <br> Unsold <br> Securities <br> to be<br> Carried <br> Forward** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to Be Paid | Equity | Common stock, par value $0.001 | 457(o) |  |  | $2576750 | $0.0001102 | $283.96 |  |  |  |  |
| Fees to Be Paid | Equity | Warrants to purchase shares of common stock<sup>(3)</sup> | 457(g) |  |  |  |  | $0 |  |  |  |  |
| Fees to Be Paid | Equity | Common stock issuable upon exercise of the warrants | 457(o) |  |  | $5153500 | $0.0001102 | $567.92 |  |  |  |  |
| Fees to Be Paid | Equity | Pre-funded warrants to purchase shares of common stock<sup>(4)</sup> | 457(g) |  |  |  |  | $0 |  |  |  |  |
| Fees to Be Paid | Equity | Common Stock issuable upon exercise of the pre-funded warrants<sup>(4)</sup> | 457(g) |  |  |  |  | $0 |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $7730250 |  | $851.88 |  |  |  |  |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  |  |  |  |  |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |  |  |  |  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $851.88 |  |  |  |  |

---

(1) Estimated
solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933. The registrant previously registered securities with a proposed maximum aggregate offering price not to exceed $39,000,000 on a registration
statement on Form S-1, as amended (File No. 333-268576), which was declared effective by the Securities and Exchange Commission on February
9, 2023. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate
offering price of $7,730,250 is hereby registered.

(2) Pursuant
to Rule 416, the securities being registered hereunder include such indeterminate number of additional securities as may be issued after
the date hereof as a result of stock splits, stock dividends or similar transactions.

(3) In
accordance with Rule 457(g) under the Securities Act, because the shares of the common stock underlying the warrants are registered hereby,
no separate registration fee is required with respect to the warrants registered hereby.

(4) The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price
of any pre-funded warrants sold in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be sold
in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock sold in the offering. Accordingly,
the proposed maximum aggregate offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise
of the pre-funded warrants), if any, is $15,576,750.